Abstract
Aberrantly glycosylated tumor antigens represent promising targets for the development of anti-cancer vaccines, yet how glycans influence immune responses is poorly understood. Recent studies have demonstrated that GalNAc-glycosylation enhances antigen uptake by dendritic cells as well as CD4(+) T-cell and humoral responses, but prevents CD8(+) T-cell activation. Here, we briefly discuss the relevance of glycans as candidate targets for anti-cancer vaccines.
Original language | English |
---|---|
Journal | OncoImmunology |
Volume | 2 |
Issue number | 4 |
Pages (from-to) | e23659 |
ISSN | 2162-4011 |
DOIs | |
Publication status | Published - 1 Apr 2013 |